OS Therapies targets mid-Q4 2026 start for UK Phase 3 OST-HER2 trial
OS Therapies plans to seek early market access for OST-HER2 in metastatic osteosarcoma via a U.K. conditional filing in the coming weeks, with MHRA set to lead the Project Orbis review. FDA alignment on an amended Phase 3 design supports a confirmatory trial start in the U.K. in mid-Q4 2026.